Bayer's Dual Track: Oncology Data Lifts Price Targets While Biofuel Bet Targets Life Beyond Roundup

Barclays and Deutsche Bank lifted Bayer targets after new SOHO-01 data on Sevabertinib, as a Missouri Roundup settlement hearing is set for September 14.

Fresh efficacy data on Bayer's lung cancer treatment has given analysts firmer ground to stand on, even as the German conglomerate simultaneously pushes into renewable fuels and braces for a pivotal courtroom date in Missouri.

SOHO-01 Results Give Analysts Something Concrete

Bayer released additional details Thursday on the performance of its lung cancer drug Sevabertinib, drawing coverage from Reuters and Morningstar. The findings from the SOHO-01 study program emerged in the wake of the drug's U.S. approval as a first-line therapy, and they now provide the substantive basis on which analysts are recalibrating the company's oncology potential.

The supplementary SOHO-01 data are meant to demonstrate how durable the efficacy actually is in HER2-mutated non-small cell lung cancer. That distinction matters to investors because a bare approval announcement says nothing about the size of the addressable patient population or how long responses last. Only the accompanying study figures allow analysts to gauge the revenue opportunity in oncology with any realism.

Barclays moved first, raising its price target on Bayer to EUR 70 on Tuesday while keeping its Overweight rating. The Deutsche Bank followed two days later, reaffirming its Buy recommendation with a EUR 60 target. Both cite progress in the oncology portfolio, which gained an additional leg when Sevabertinib won accelerated FDA approval under the brand name Hyrnuo.

A Second Front: Neste Partnership and Pipeline Expansion

Bayer is hunting for fresh growth drivers beyond the drawn-out Roundup litigation, and a newly signed commercial agreement with Finland's Neste Oyj aims to put the biofuels business on new footing. At the center of the cooperation sits Newgold Winter Canola, a rapeseed variety the two companies intend to scale for biofuel applications. For Bayer, the project fits the agricultural division's strategic tilt toward new product launches and higher-margin niches.

The company has not disclosed volumes or revenue targets for the partnership, but the message to the market is unambiguous: Bayer wants growth fields outside its traditional pesticide and seed operations. On the pharmaceutical side, Bayer launched a Phase II trial Wednesday with an investigational GIRK4 inhibitor in patients with atrial fibrillation — another building block in its effort to broaden the oncology and cardiology pipeline. The FDA green light for Hyrnuo in certain lung cancer patients, which made waves the previous Thursday, remains the most prominent recent milestone.

The agricultural unit had already presented progress on its so-called ten-blockbuster strategy at an investor day in early September, with Plenexos and the Preceon Smart Corn System as products already on the market. Whether the Neste tie-up becomes the hoped-for growth engine depends largely on how quickly Newgold Winter Canola can be scaled in practice.

Roundup Hearing Set for September 14

Bayer remains under pressure in the Roundup legal battle: a settlement hearing is scheduled for September 14 in the U.S. state of Missouri, where a USD 7.25 billion settlement will be reviewed. That date is likely to return to the spotlight in the coming days, independent of the oncology news.

Market Response Stays Muted

Despite the positive analyst reactions, the stock has shown little movement of late. On Friday the shares closed at EUR 48.19, just below the 50-day average of EUR 48.57 — a gap of 0.8%. The day's decline amounted to 0.6%, and over the past seven trading sessions the stock has lost 1.3%. Since the start of the year, however, a gain of 30% is on the books, a sign that the market has already priced in much of the fundamental reassessment of the company.

The subdued daily reaction can also be explained by the fact that the study details themselves contained no surprising new facts, merely underpinning the already-known approval. The cautious tone suggests investors remain wary as long as the legal risks surrounding Roundup are not definitively resolved.

For the stock's next move, the decisive question is whether the growth expectations sketched by Barclays and Deutsche Bank in the oncology business are confirmed in upcoming quarterly figures. Until then, the settlement hearing in Missouri is the next concrete event that could move the shares in the short term. The broader picture remains complex: encouraging price targets from Barclays and Deutsche Bank on one side, and the unresolved question of how the Roundup legal complex will affect the balance sheet over the long haul on the other.